Jim Hollingshead: Thanks. Yeah, we’re so excited about getting Omnipod 5 into multiple markets in Europe. As we said — as we detailed in the prepared remarks the U.K. launch is going really well. Germany is strong out of the gate. In direct answer to your question we don’t see any barriers to driving really strong and robust growth where we launch Omnipod 5. And as I think I said in the prepared remarks we’re very confident it’s going to be a leading offer wherever we’re able to put it in the market. So it’s such a great solution it’s so easy for customers to use. It drives such great real-world results. And as we get more evidence and we can drive access conversations we’re also confident we can get a price premium for the value that Omnipod 5 creates. And so we’re all systems — full speed ahead in getting into our international markets with Omnipod 5.
Operator: Our next question comes from Jeff Johnson from Baird. Please go ahead. Your line is open.
Jeff Johnson: Thank you. Good afternoon guys. Nice quarter. Jim maybe if I could pin you down on a little bit more detail on the Sensor Integration side. So in LMR on G7 integration in the U.S. early in the year I know it’s going to depend on what you see in the field what the feedback is and all that. But just generally do we tend to think of LMRs I could go back and check my notes I guess in O5. Is that like a three-month LMR and then a full launch or just how to think about that? And then on the L2 front obviously you gave some updates internationally. How should we think about the time line L2 in the U.S.? And L3 OUS and U.S. any updates there at all, just once L2 comes out integration is it a 6-month or is it a year? How far down the road might we see L3? Thanks.
Jim Hollingshead: Yes. Thanks Jeff. I’ll go in reverse order. We’re not providing additional guidance on timing for the Libre family of sensors at this point. We do feel good about the integration we have going with our RADIANT trial. And the customer experience on the RADIANT — which is the Libre 2 integration that we’re doing in Europe. The customer experience on the RADIANT trial has been terrific. And so, we’re very bullish on that. And obviously to be in trial with that system we have to have a working integration. So, we’re bullish on that, but we’re not ready to provide timing on Libre for any specific markets at this moment. On the LMR question, it’s a great question. We don’t — we think of LMR as exercises to test hypotheses and make sure the system is working the way we want it to.
So we don’t actually put a time line on it. We put a set of conditions on it. And so, as we get into market with LMR, we’ll see what we see. Obviously, we wouldn’t be going into LMR with the G7 integration, if we weren’t confident that the system was working as expected. But with all of these things, you have to get the product out in a while to see how it performs. And so we’ll get the LMR out there and we’ll move as quickly as we can and we’re really excited about bringing that G7 integration to market.
Operator: Our next question comes from Matt Taylor from Jefferies. Please go ahead. Your line is now open.
Matt Taylor: Hey, thanks for taking the question. I guess I wanted to ask you more about your efforts in type 2. Obviously, you’re having some good success there today with 20% coming into the fold and that being a consistent level over time a healthy level. But I guess my question is, as you get the hopefully additional indications that are able to market, do you expect the proportion of type 2s to increase in the future? Maybe offer some thoughts on where that could go to. And also, could that even further broaden the prescriber base once you have that?
Jim Hollingshead: Thanks, Matt. Those are both great questions. First thing I’ll say is, we’re so strong in type 1, all right? So our offering in type 1 is bringing so many customers into the market from MDI that we expect to continue to drive penetration to the type one market and bring those customers who are currently not on a technology-based solution onto Pod therapy. And so — and therefore that portion of the growth will continue. We’re very bullish on growing MDI in type 1. Type two is a massively underpenetrated market. And we’ve been through the numbers on this a couple of times. And it’s in our deck that we put up our investor deck that shows the market size for type two — the progression of type two disease. But we’ve got 30-some-odd million people diagnosed with type 2 in the US who then progress on the basal and then on to intensive insulin therapy.
Right now, there are about 2.5 million people in the US market who need intensive insulin as a part of their type two diabetes care. And they’re just really underpenetrated as a market for pump therapy overall and therefore for Pod therapy. And we’re very, very bullish on that. So if you think about — we’ll continue to penetrate type 1. Type two is actually a larger end market for intensive insulin therapy than type 1. So the proportion — I do think to your point, the proportion will probably swing as we’re able to get the indication for use and drive adoption in the market, but the numbers will go up. The total adoption number of customers will go up on both fronts.
Operator: Our next question comes from Matthew O’Brien from Piper Sandler. Please go ahead. Your line is open.
Unidentified Analyst: Hey this is Phil on for Matt. Thanks for taking our questions and congrats on the quarter. Just wait Jim, as we think about the key growth factors for the business being on the volume side of things, the ratio of MDI to conversions has marched from 50-40 to now 80-20 in the US. Are you seeing any kind of slowdown in your ability to convert competitive pumpers? Also, if you could provide that same ratio in OUS given the launch there, what does that MDI-to-conversion ratio look like in Europe?
Jim Hollingshead: Thanks, Phil. The Q3 doesn’t look hugely different from Q2 in terms of the mix of components of where customers are coming from. The only difference was — and if I just back up, I’ll go into the weeds for a second I apologize for going into the weeds. When we talk about sources of customers, whether it’s type 1, type 2, MDI competitive conversion, we have different sources of data that allow us to estimate that including voluntary — so when a customer enrolls on Omnipod, they will tell us where they’re coming from usually. So it’s voluntary information. It’s not 100% data capture and what that means is there’s a little bit of an estimation kind of range on those things. And so, Q3 compared to Q2 didn’t look all that different.
The only thing that looks different enough for us to change the number was competitive conversions went — as you said, last quarter, we said it was 75-25. In this quarter, we said 80-20. But even that in terms of total number and range of estimate was not that huge a change. And we’ve been really happy with competitive conversions over the course of the launch of Omnipod 5. We’re really clear at launch that the number, the volume of people converting from tubed pumps was a pleasant surprise for us. And we sustained that for a long time and probably a little longer on balance above historical trends of 80/20 sustained it for a little bit longer than we thought. So it’s not really a surprise for us to get back to this 80/20 mix. And what it means is we continue to bring we’re the clear market leader in bringing customers from MDI on to — you could talk about again the broad category of AID but on to AID Pod therapy on Omnipod 5.
